Evidence map›Paper›PMID 41729786›Full record

Observational studyOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology2026

From Sound to Stability: Lessons Learned From the CRUSH Study on Hearing Loss Progression and Vestibular Phenotype in Usher Syndrome Type 2A.

Dirk H Wijn, Mirthe L A Fehrmann, Sybren M M Robijn, Hedwig M Velde, Jeroen J Smits, Erwin van Wijk, Andy J Beynon, Froukje L J Cals, Carel B Hoyng, Suzanne Yzer and 2 more

Abstract readObservational Study
In one paragraph

Observational study in Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dirk H WijnDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Mirthe L A FehrmannDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Sybren M M RobijnDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Hedwig M VeldeDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Jeroen J SmitsDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Erwin van WijkDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Andy J BeynonDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Froukje L J CalsDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Carel B HoyngDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Suzanne YzerDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Cris P LantingDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.
Ronald J E PenningsDepartment of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

Stichting Ushersyndroom ,Radboud FondsStichting Ushersyndroom, Radboud Fonds
6 · The paper itself

Abstract

objectiveThis study aims to analyze the progression of hearing loss using prospectively collected data and describe the vestibular phenotype of Usher syndrome type 2A (USH 2a ). STUDY

designLongitudinal, prospective, observational natural history study. PATIENTS: Patients with USH2a and USH2A -associated non-syndromic retinitis pigmentosa (nsRP).

main outcome measuresHearing loss progression was measured by pure tone audiometry (PTA) and phoneme scores. Vestibular function was assessed by velocity step tests (VSTs), video head impulse tests (vHITs), caloric reflex tests, and vestibular evoked myogenic potentials (VEMPs). Patient-reported symptoms were assessed by questionnaires (Usher Lifestyle Survey, SF-12, PHQ-9, DHI, and SSQ).

resultsThirty-three patients with USH2a and 2 patients with nsRP were included. PTA 0.5-4kHz thresholds showed a significant decrease of 2.3 dB ( P =0.017) over 4 years. The progression of hearing loss was most pronounced in the mid-to-high frequencies. No significant differences were observed in phoneme scores as measured by the Speech Reception Threshold (SRT). The 2 patients with nsRP had normal hearing. Vestibular evaluation showed abnormal cervical VEMPs in 34% and abnormal ocular VEMPs in 75% of USH2a patients. VSTs, caloric reflex tests, and vHIT results were within normal limits in more than 90% of subjects. Patient questionnaires revealed no major balance problems as indicated by the DHI.

conclusionsThis analysis provides robust evidence of measurable hearing loss progression in PTA 0.5-4kHz thresholds in USH2a patients beyond presbycusis. Speech understanding, as measured by SRT, remains relatively stable. Vestibular evaluation revealed no semicircular canal dysfunction, although VEMP results suggest a potential subclinical otolith organ impairment in USH2a patients.

Indexed as

Usher SyndromesVestibule, LabyrinthAdultAudiometry, Pure-ToneAuditory AcuityCaloric TestsDisease ProgressionExtracellular Matrix ProteinsFemaleHumansLongitudinal StudiesMaleMiddle AgedPhenotypeProspective StudiesRetinitis PigmentosaExtracellular Matrix ProteinsUSH2A protein, humanNatural history studySensorineural hearing lossUsher syndromeVestibular testing

Identifiers

PMID41729786
PMCPMC12970546

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.